NTLA

Intellia Therapeutics, Inc.

Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia\'s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products.

Intellia Therapeutics, Inc. (NTLA) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Profitability (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
C+
Factor Score 2.8 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
C-
Factor Score 1.9 / 5.0
Momentum
C+
Factor Score 2.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.9
EV / EBITDA -2.9
Rev Growth YoY -48.0%
Gross Margin 0.0%
Price Return 3M -11.4%
Price Return 12M 3.6%
Catalyst Signal 0.00
Market Cap $1.5B
TTM Revenue $52.9M
Price / Sales 28.0
ROE -62.6%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.8) C+ (2.7) C- (1.9) C+ (2.7) C+ (2.6) C+ (2.6)
2026-11-06 B- (2.9) C+ (2.7) C- (1.9) C+ (2.6) C+ (2.7) C+ (2.6)
2026-10-30 C+ (2.8) C+ (2.6) C- (1.9) B- (2.9) A+ (5.0) B- (3.1)
2026-10-23 B- (2.9) C+ (2.6) C- (1.9) C (2.3) A+ (5.0) B- (2.9)
2026-10-16 B- (2.9) C+ (2.6) C- (1.9) C (2.3) A+ (5.0) B- (2.9)
Page 1 of 8
…